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In 1979, the National Cancer Institute in Bethesda, Mary. 
iand initiated a randomized, prospective trial to compare 
surgery versus radiation therapy in the treatment of stages 
I and Il  breast cancer. Surgical treatment consists of total 
mastectomy with axillary lymph node dissection (modified 
radical mastectomy) and breast reconstruction; radiation 
treatment consists of gross tumor excision, axillary lymph 
node dissection, and comprehensive irradiation including a 
boost dose to the tumor bed. Ail patients with pathologi- 
cally positive axillary nodes receive 11 cycles of adjuvant 
Adriamycin| | chemotherapy. As of December 
1984, there have been 175 patients entered in the study. 
Twenty-three patients have deveioped disease recurrence 
(12 mastectomy, 11 radiation), but it is too early to obtain 
definitive treatment-related results. 
Over the last decade, changing concepts of tumor 
biology, improved therapeutic technology, and pa- 
tient demands for treatment alternatives have 
wrought major change and heightened controversy 
surrounding the treatment of clinically localized 
breast cancer. The ideal therapy would not only be 
effective in curing the patient of cancer, but would 
do so with a minimum of physical disfigurement and 
psychological trauma. Although physicians agree 
on the desirability of these ends, argument over the 
best means to accomplish them is often heated. 
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Reports from single institutions [1-8] describing 
the outcome of various treatment techniques have 
been extremely encouraging in the movement away 
from disfiguring surgery. From such experiences, 
there are strong indications that treatment programs 
other than radical surgery, usually radiation therapy 
incorporated with limited surgical procedures, may 
well be capable of achieving comparable cure rates. 
However, the possibility of bias in these results due 
to patient selection has precluded unconditional 
acceptance of the equivalence of such alternative 
treatments. Appropriate clinical trials are necessary 
to answer the question definitively. 
The results from 2 recent randomized trials, one 
from the Tumor Institute of Milan [9] and another 
from the National Surgical Adjuvant Breast and 
Bowel Project (NSABP) [10], which compare a 
surgical procedure incorporating breast amputation 
to treatment allowing for breast preservation are 
now available. Results from these important studies 
demonstrate that treatment that conserves the 
breast does not compromise survival in the study 
groups so tested at the present time of analysis. 
Neither study included ail patients with clinical 
stages I and II breast cancer. In the Milan trial, only 
patients with clinical stage TIN0 cancers were ac- 
cepted for treatment, while in the NSABP study 
tumor size was limited to 4 cm and patients with 
central tumors were excluded. Also, although both 
trials tested a radical surgical procedure incorporat- 
ing breast removal against a breast-preserving treat- 
ment, differences in the specific treatments in- 
volved make direct comparisons difficult. In the 
Milan study, classic Halsted radical mastectomy, a 
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more extensive surgical procedure than the current 
standard, was compared to formal quadrantectomy 
with axillary dissection followed by breast irradia- 
tion. In the NSABP trial, the control arm, consist- 
ing of total mastectomy and axillary dissection 
(which has been the accepted and usual surgical 
approach in the United States), was compared to 
"segmental mastectomy" with and without radia- 
tion. Patients undergoing segmental mastectomy 
were required to have pathologically negative mar- 
gins in the resected specimen. If margins were 
positive, the patient underwent an immediate total 
mastectomy. The surgery performed in a segmental 
mastectomy, particularly in terres of amount of 
surrounding normal tissue resected, is subject to 
great variability from patient to patient and surgeon 
to surgeon. Although both quadrantectomy and 
segmental mastectomy with negative margins pre- 
serve some portion of the breast, in many instances 
such resections result in a compromised cosmetic 
outcome. 
In 1979, at the National Cancer Institute in 
Bethesda, Maryland, we initiated a randomized, 
prospective study. The purpose of the trial is to 
compare the current surgical treatment to compre- 
hensive radiation therapy (Table 1). 
Surgical management consists of total 
mastectomy with axillary dissection, followed by 
(optional) breast reconstruction. Several recon- 
struction options are available for our surgically 
managed patients. In the past, such procedures 
have involved placement of a prosthesis as well as 
creation of a breast mound using latissimus dorsi or 
rectus abdominus muscle. With use of these tech- 
niques, in order to optimize our ultimate cosmetic 
result, we delay breast reconstruction until the 
patient has recovered from her mastectomy and the 
local tissues have healed and stabilized. In patients 
not receiving chemotherapy, we can proceed as 
early as 3 months after the mastectomy. Patients 
who require chemotherapy have these surgical pro- 
cedures delayed until the completion of ail courses 
of drug in order to avoid the possibility of infection 
and compromised wound healing. Recently, we 
have been able to offer patients an "immediate" 
reconstruction option. This involves placement at 
the rime of mastectomy of a Silastic | tissue ex- 
pander beneath the pectoralis major muscle. The 
device has an injection port which can be felt 
through the skin. Once the incision has healed, 
generally about 2 weeks, sterile saline can be 
percutaneously injected at periodic intervals 
through the port so as to expand the device gradu- 
ally and with it the overlying tissues. Once an 
appropriate contour has been achieved, the tissue 
expander can be removed and the nipple-areola 
complex reconstructed at a second surgical proce- 
dure. This particular reconstruction option allows 
for rapid reconstitution of patient contour and elim- 
inates the need for an external prosthesis even in 
patients who require chemotherapy and in whom 
the second procedure must be delayed. 
Radiation treatment consists of gross tumor re- 
moval, axiUary node dissection, and comprehensive 
regional irradiation. Tumor removal involves exci- 
sion of the mass with a minimum of surrounding 
normal tissue, and does not require that the margins 
be pathologically free of microscopic tumor. Axil- 
lary dissection is performed through a separate 
incision and is virtually identical to the axillary 
surgery incorporated with total mastectomy. This 
assures us of an equivalent pathological nodal stag- 
ing in the 2 treatment arms. Radiation treatment 
fields vary with tumor location and pathological 
status of axillary lymph nodes. The entire breast is 
irradiated in all patients. Patients with inner quad- 
rant lesions receive, in addition, radiation to the 
internal mammary lymph nodes. Patients with 
pathologicaUy positive axillary lymph nodes also 
receive radiation therapy to the internal mammary 
nodes as well as to the supraclavicular area. This is 
summarized in Table 2. We avoid irradiation of the 
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Table 2. Radiation therapy treatment volume related to 
location of breast primary and pathologic node status. 
Location of 
breast tumor Negative 
Axillary lymph nodes 
Positive 
Lateral Breast 
Central and Breast + internal 
medial mammary 
nodes 




fully dissected axilla except when there has been 
pathological demonstration of extranodal extension 
of cancer into the axillary fat. All patients undergo 
simulation and treatment planning computed 
tomographic (CT) scan. The breast is treated with 
opposing tangential fields which are angled to min- 
imize beam divergence through the lung. Lung 
volumes are obtained on each patient through the 
use of CT scans, and lung density corrections are 
used in the calculation of dose to the tangential 
breast fields. Wedge beam modifiers are added as 
individually necessary to optimize dose homogene- 
ity. An isodose plan is generated for at least 3 
levels, including the central axis, and a prescription 
isodose is chosen that encompasses the entire 
breast tissue homogeneously. When internal mam- 
mary nodes are included in the treated volume, we 
prefer to include this region in the tangential fields, 
although in the unusual situation we have applied 
direct en face internal mammary field. When supra- 
clavicular nodes are treated, this is accomplished 
with a direct anterior field, angled so that the exit 
dose avoids the spinal cord. AI1 field edges are 
carefully matched using customized blocks and field 
angles to avoid over or under dosage at the edges of 
abutting fields. Patients are treated in the supine 
position on a 4-MeV linear accelerator using 180- 
rad daily fractions to a total dose of 4,680 rad. In 
addition to x-ray treatment of the region, we incor- 
porate a boost dose of radiation to the tumor bed. 
This is nearly always accomplished through use of 
an interstitial implant for which we use seeds of 
iridium 192, but in rare circumstances we have 
administered the boost dose using an electron 
beam. Total dose to the region of the tumor bed is 
about 6,300 rad. 
AIl patients who demonstrate pathological in- 
volvement of 1 or more axillary lymph nodes are 
treated with 11 cycles of adjuvant chemotherapy 
consisting of Adriamycin | 30 mg/m 2 and Cytoxan | 
200 mg/m 2. Drug dosages are escalated or reduced 
aceording to the schedule shown in Table 3. 
Patients are eligible for this study if they have 
invasive breast cancer with a primary tumor up to 5 
cm in diameter, clinically negative or clinically 
positive but movable axillary lymph nodes, and no 
evidence of distant metastases (AJC stage T1_2, 
N0_1, M0). Patients are excluded if they bave mul- 
tiple primary breast tumors or a history of prior 
malignancy other than nonmelanoma skin cancer. 
AI1 breast cancer treatment other than excisional 
biopsy of the primary tumor is performed at the 
National Cancer Institute. The patients are assigned 
by stratified block randomization.to 1 of the 2 
treatment arms, with stratification by age (less than 
50, greater than or equal to 50 years), clinical node 
status, and history of cardiac disease. We do not 
employ prerandomization. 
As of December 31, 1984, there bave been 175 
patients entered in the study, of whom 85 random- 
ized to surgery and 90 to radiation therapy. Median 
patient age is 50 years, with a range of 25 to 79. The 
median number of axillary nodes examined is 23, 
with a range of 8 to 60, and does not differ between 
the two arms. Pathologically positive lymph nodes 
were found in 72 patients (41%), of whom 38 had 
been assigned to mastectomy and 34 to radiation. 
In addition to determination of treatment out- 
corne in terres of survival and survival free of 
disease, we are investigating several other issues 
related to early breast cancer in our study patients. 
We have recently begun a study to test the feasibil- 
ity of imaging axillary lymph node metastasis by the 
subcutaneous injection of monoclonal 131I-labeled 
anticarcinoma antibodies. Labeled antibody is in- 
jected into the finger webs, and the patient then 
undergoes serial scanning over several days. The 
axillary nodes are dissected according to our usual 
procedure, and the pathological node findings are 
compared to the scan results. We have reported 
previously that our technique of administering radi- 
ation therapy does not compromise delivery of 
systemic adjuvant chemotherapy, with a 100% me- 
dian dose of Adriamycin| delivered in both arms, 
and median doses of delivered Cytoxan| 110% and 
115% in the radiation and surgery arms, respec- 
tively [11]. We feel that routine incorporation of 
reconstruction after mastectomy will allow us to 
compare realistically the psychological impact of 
out 2 local treatment modalities. We have previ- 
ously reported on psychosocial outcomes of pri- 
mary breast cancer therapy in our study population 
[12]. Upon completion of local therapy, patients 
were assessed for mood (anxiety, guilt, anger), 
attitudinal responses (feelings of concern that can- 
cer might recur), and behavioral reaction (possible 
problems in eating, sleeping, or sexual response). 
Our patient population is uniquely suited to study 
the psychosocial impact of therapy since ail study 
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Table 3. Summary of chemotherapy. 
Adriamycin | 30 mg/m 2 day 1 
Dose escalation 
Adriamycin| not permitted 
Cytoxan | 
Increase each cycle if necessary 
Increase in incrernents of 25% 
Increase if nadir WBC >2,500 and/or polys > 1,200 and platelets > 100,000 
Dose reduction 
WBC Polys Plts. 
Nadir < 1,800 and/or < 1,000 <75,000 
Nadir < 1,500 and/or <500 <50,000 
Day 1 <3,500 but >2,000 > 125,000 
Day 1 <3,500 and <2,000 < 125,000 
Cytoxan | 200 mg/rn 2 
day 3-6 
Day 1 <3,000 and < 1,800 < 100,000 
Dose re-escalation (After a dose reduction if the following criteria are met:) 
WBC Polys Plts. 
Nadir >2,000 > 1,200 >75,000 
Day 1 >3,500 >2,000 > 125,000 
Increase Adriamycin | first by 25% increments until full dose, then increase Cytoxan | by 25% increments. 
Modification 
75% of A and C 
50% of A and C 
Full drug 
Hold up to 2 wks: if recov- 
ered, 75% of A and C; if not 
recovered, 50% of A and C 
Hold drugs 
A = Adriamycin | C = Cytoxan | 
patients had accepted either mastectomy or radia- 
tion at study entry,  were assigned at random to 
treatment,  and are all seen jointly by the same 
health care team. When evaluated initially, the only 
psychosocial  item that was statistically, signifi- 
cantly different between the 2 groups was a more 
negative reaction to self nude in mastectomy pa- 
tients. Both groups reported fairly high degrees of  
anxiety and depression. A prospective psychosocial  
assessment of our patients examining the psycho- 
social adaptation to treatment over  time is currently 
in progress. We are examining the functional out- 
come of the 2 local treatments in terms of shoulder 
range of motion, changes in arm circumference, and 
effect of various rehabilitative maneuvers  on these 
parameters .  
I t i s  much too early to give definitive treatment- 
related results at this rime. Twenty-three patients 
have developed disease recurrence to date (12 
mastec tomy patients, 11 radiation patients). Iso- 
lated local-regional recurrence in the breast/chest 
wall and/or ipsilateral axillary, supraclavicular, or 
internal mammary lymph nodes has occurred in 4 
patients, 2 who underwent  mastectomy and 2 who 
had radiation therapy. The 2 patients who under- 
went radiation therapy and developed local-regional 
recurrence had disease limited to the breast. Both 
underwent  total mastectomy and are currently alive 
without evidence of disease 14 and 2 months after 
salvage surgery. If, with additional patients and 
longer follow-up, surgery and radiotherapy are 
shown to be equivalent in terms of cancer  control 
and survival, the choice of best t reatment  will be 
determined by issues of toxicity and cosmesis. 
R›233 
En 1979 l 'Institut National du Cancer  de Bethesda a 
lanc› une › prospective randomis› permettant  
de comparer  les r› respectifs de la chirurgie 
et de la radioth› en ce qui concerne les stades 
I et II du cancer  du sein. Le  traitement chirurgical 
consiste en la mastectomie totale compl›233 par le 
curage ganglionnaire axillaire (mastectomie totale 
modifi› le traitement dit radioth› consiste 
en l 'ex›232 large de la tumeur associ› au curage 
ganglionnaire axillaire et ” l 'administration d 'une 
dose ›233 de rayons au niveau du lit tumoral. 
Toutes les op›233 dont les ganglions sont envahis 
re™ en outre 11 cycles d 'une combinaison 
d 'Adriamycine et Cytoxan.  De 1979 ” D› 
1984, 175 malades ont fait l 'objet  de cette › 
Vingt-trois ont accus› une r› (12 aprš 
mastectomie et 11 aprš trai tement dit radioth› 
pique) mais il est encore trop t¤ pour tirer des 
conclusions d› de ces r› 
Resumen 
EI Instituto Nacional de Cgmcer de Bethesda inici6 
en 1979 un ensayo prospectivo y aleatorio orientado 
a comparar  el tratamiento quirt~rgico versus 
radioterapia en el manejo riel cgmcer mamario en 
estados I y II. E1 tratamiento quirfirgico consisti6 
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de mastectomfa total con disecci6n ganglionar 
axilar (rnastectomfa radical modificada) y recon- 
strucci6n mamaria; el manejo radioterap› 
consisti6 de resecci6n del tumor, disecci6n de los 
ganglios linffiticos axilares e irradiaci6n com- 
prensiva incluyendo una dosis de refuerzo al lecho 
tumoral. Todos los pacientes con ganglios axilares 
histol6gicamente positivos recibieron l l ciclos de 
quimioterapia adyuvante con Adriamicina/Citoxfin. 
Hasta  diciembre de 1984, 175 pacientes habfan 
entrado al estudio. Veintitr› pacientes han desar- 
rollado recurrencia de la enfermedad (12 
mastectornfa, 11 irradiaci6n), pero es todav/a muy 
temprano para derivar resultados definitivos. 
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